RDPTF.US Radiopharm Theranostics Limited

Healthcare Biotechnology USA Stocks
0.0067 USD
Close of Nov 17, 2026
0.0067 0.0200
Market cap
USD 31.4M
P/E
-
P/B
1.88x
ROE
-230.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is RDPTF.US undervalued?

Graham number

The Graham number of Radiopharm Theranostics Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Radiopharm Theranostics Limited fundamental analysis

No fundamental analysis for Radiopharm Theranostics Limited yet.

Radiopharm Theranostics Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Radiopharm Theranostics Limited

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; …

Full company profile